![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 17, 14712-14716, April 26, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Molecular Medicine, Cornell University,
Ithaca, New York 14853
Received for publication, December 21, 2001, and in revised form, February 13, 2002
Tissue transglutaminase (TGase) is a dual
function enzyme that couples an ability to bind GTP with transamidation
activity. Retinoic acid (RA) consistently induces TGase expression and
activation, and it was recently shown that increased TGase expression
protected cells from apoptosis. To better understand how RA regulates
TGase, we considered whether RA employed pro-survival signaling
pathways to mediate TGase expression and activation. It was found that RA stimulation of NIH3T3 cells activated ERK and phosphoinositide 3-kinase (PI3K); however, only PI3K activation was necessary for RA-induced TGase expression. The overexpression of a constitutively active form of PI3K did not induce TGase expression, indicating that
PI3K signaling was necessary but not sufficient for TGase expression.
The exposure of cells expressing exogenous TGase to the PI3K inhibitor,
LY294002, reduced the ability of TGase to be photoaffinity-labeled with
[ Tissue transglutaminase
(TGase)1 is a unique dual
function protein that contains an enzymatic transamidation activity and
a GTP-binding capability similar to other classical G-proteins (1). The
transamidation activity of the TGase catalyzes a reaction in which
donor glutamine residues from proteins are covalently linked to
acceptor primary amino groups of other proteins or polyamines. The
generation of these protein linkages is believed to modulate a variety
of cellular processes including the maintenance of extracellular matrix, endocytosis, differentiation, and apoptosis (2-6). Moreover, aberrant TGase enzymatic activity has been linked to several
neurodegenerative disorders (1), indicating that proper regulation of
TGase activity is required for normal cellular functions.
One way in which TGase activity is managed is through the regulation of
its expression. Many cell types express the TGase protein at low
levels, and increases in its expression often occur only after
prolonged exposure to certain stimuli (7, 8). A consistent inducer of
TGase expression is retinoic acid (RA) (8-12), which imparts its
cellular effects by binding to a family of retinoic acid receptors
(RARs). Retinoic acid-bound RARs function as transcriptional activators
that bind to RA response elements found in the promoters of various
genes (13, 14). Deletion analysis of the promoter of the TGase gene
identified two RA response element motifs, which were required for
RA-induced TGase transcription (15). Other transcriptional regulators
are thought to influence TGase expression (16), but the identity of
these factors and their importance for RA-mediated TGase expression are unclear.
Once TGase is expressed, its enzymatic activity can be regulated by
binding cofactors such as GTP and calcium (Ca2+). Studies
have demonstrated that GTP-bound TGase was limited in its ability to
catalyze transamidation, whereas GTP hydrolysis and the binding of
Ca2+ enhanced transamidation activity (17, 18). However,
others have reported that both GTP and GDP inhibit the transamidation activity of the TGase (19), suggesting that GTP binding is not a
specific regulator of transamidation but rather may primarily serve to
transduce signals. For example, the Here we used RA-induced TGase expression and activation as a model
system to better understand how TGase is regulated in cells. Because we
recently reported that TGase activity was implicated in cell survival
(7), we considered whether RA utilizes pro-survival pathways to mediate
TGase expression or activation. We found that both phosphoinositide
3-kinase (PI3K) and extracellular signal-regulated kinase (ERK) were
activated by RA, but only PI3K activity was necessary for RA to induce
TGase expression. The inhibition of PI3K or TGase activity converted RA
from a differentiation factor into an apoptotic signal, suggesting that
the survival effect of PI3K may at least in part be attributed to its
ability to up-regulate TGase. We further determined that GTP-binding to
the TGase was dependent on PI3K. To our knowledge, these findings
provide the first demonstration that the induction of TGase expression
and GTP binding activity by RA requires the pro-survival factor,
PI3K.
Materials--
PD98095 and LY294002 were purchased from
Calbiochem, and EGF and LipofectAMINE PLUS transfection reagent were
obtained from Invitrogen. RA,
all-trans-N-(4-hydroxyphenyl)retinamide
(HPR), and monodansylcadaverine (MDC) were obtained from Sigma. The
anti-TGase antibody was from Neomarkers, the anti-HA antibody was from
Covance, and the anti-phospho-ERK, anti-ERK, anti-active AKT,
and anti-AKT antibodies were all obtained from New England
Biolabs. [ Cell Culture--
HL60 cells were maintained in RPMI 1640 medium
containing 10% fetal bovine serum and 100 units/ml penicillin, and
NIH3T3 cells were maintained in Dulbecco's modified Eagle's medium
containing 10% calf serum with 100 units/ml penicillin. Both cell
lines were maintained in a humidified atmosphere with 5%
CO2 at 37 °C. For the various treatments described, the
cells were grown to subconfluence in medium containing 10%
serum, and then medium containing 1% serum with 5 µM RA
or HPR or 100 ng/ml EGF, ±6 µM LY294002, or 10 µM PD98095 was added for the times indicated under
"Results and Discussion." Cells were rinsed with phosphate-buffered
saline and then lysed with cell lysis buffer (10 mM
Na2HPO4, 150 mM NaCl, 1% Triton
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% NaF, 1 mM NaVO4, 25 mM
Western Blot Analysis--
Total cell lysate of each sample was
combined with Laemmli sample buffer, boiled for 5 min, and subjected to
SDS-PAGE for the resolution of each protein analyzed. The proteins were
transferred to nitrocellulose filters and blocked with TBST (20 mM Tris, 137 mM NaCl, pH 7.4, and 0.02% Tween
20) containing 5% nonfat dry milk. The filters were incubated with the
various primary antibodies diluted in TBST for 2 h at room
temperature and then washed three times with TBST. To detect the
primary antibodies, anti-mouse or rabbit conjugated to horseradish
peroxidase (Amersham Biosciences) diluted 1:5000 in TBST was incubated
with the filters for 1 h, followed by three washes with TBST. The
protein bands were visualized on x-ray film after exposing the filters
to chemiluminescence reagent (ECL, Amersham Biosciences).
Photoaffinity Labeling of the TGase--
Photoaffinity labeling
of the TGase was performed by incubating whole cell lysates with 3 µCi of [ Nuclear Condensation or Blebbing Assay--
Cells were seeded on
coverslips in 6-well dishes and grown in complete medium for 2 days.
The cells were then incubated in serum-free medium containing 5 µM RA or HPR, ±75 µM (MDC), or 6 µM LY294002 for 1 day. The cultures were then fixed and
stained with 4,6-diamidino-2-phenylindole (2 µg/ml) for viewing by
fluorescence microscopy. Apoptotic cells were identified by condensed
nuclei and/or blebbing.
Several studies have demonstrated that the expression and
activation of the TGase are tightly coupled to the effects of RA (8-12). However, it is unclear whether the increases in TGase protein
levels and GTP binding activity induced by RA occur solely through
up-regulation of the transcriptional activities of the RARs or whether
the activation of additional signaling components is needed. Because we
recently implicated TGase as a survival factor (7), we were interested
in determining whether the anti-apoptotic molecules PI3K and ERK
influence TGase expression and/or activation.
Fig. 1A shows that when NIH3T3
cells were incubated with RA there was a progressive increase in TGase
protein expression as determined by Western blot analysis and GTP
binding activity. GTP binding activity was measured by the
incorporation of [ The fact that both ERK and PI3K activities appear to be enhanced by RA,
which is coupled with the finding that RA induces TGase expression,
raises the possibility that the activation of these kinases may play a
role in up-regulating the expression of the TGase. To address this
question, we took advantage of chemical inhibitors that specifically
block the activations of either MEK, the immediate activator of ERK, or
PI3K. NIH3T3 cells were stimulated with RA for 3 days with or without
the addition of the MEK inhibitor, PD98095, or the PI3K inhibitor,
LY294002, at concentrations known to inhibit the activity of each
kinase (26), and the resulting expression and GTP binding activity of
the TGase were determined. As shown in Fig.
2, left, incubating the cells
with PD98095 appeared to have no effect on the ability of RA to induce
TGase expression or GTP binding activity. Thus, the ERK pathway may be
used by this retinoid to mediate the expression of some RA-responsive genes that are distinct from those that influence the expression or GTP
binding activity of the TGase. In contrast, the exposure of RA-treated
cells to LY294002 severely diminished the protein expression level and
corresponding GTP binding activity of the TGase. In several
experiments, the LY294002-mediated inhibition of TGase expression and
activity ranged from 60 to 90% (Fig. 2 and data not shown). The
overexpression of the p85 regulatory subunit of PI3K in cells also
inhibited the RA-induced TGase expression and GTP binding activity
similar to LY294002 (Fig. 3), further implicating PI3K signaling in the transcriptional regulation of the
TGase. Reprobing the same blots from Fig. 2 with an antibody against
actin showed equivalent amounts of this protein in each lane,
indicating that the decrease in TGase expression by LY294002 was not a
result of a general down-regulation in protein expression (Fig. 2,
left). Similar experiments conducted on the human leukemia cell line, HL60, and several other cell types consistently found that
RA-induced TGase expression was inhibited when the cells were
co-incubated with the PI3K chemical inhibitor (Fig. 2, right and data not shown).
Phosphoinositide 3-Kinase Activity Is Required for Retinoic
Acid-induced Expression and Activation of the Tissue
Transglutaminase*
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-32P]GTP, providing evidence that PI3K
regulates the GTP binding activity of TGase as well as its expression.
Moreover, cell viability assays showed that incubation of RA-treated
cells with LY294002 together with the TGase inhibitor,
monodansylcadaverine (MDC), converted RA from a differentiation
factor to an apoptotic stimulus. These findings demonstrate that
PI3K activity is required for the RA-stimulated expression and GTP
binding activity of TGase, thereby linking the up-regulation of TGase
with a well established cell survival factor.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1-adrenergic
receptor-mediated stimulation of phospholipase C activity was shown to
be mediated by an 80-kDa GTP-binding protein, which was later
identified as TGase (20).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-32P]GTP was purchased from
PerkinElmer Life Sciences, and all other materials were from Fisher
unless otherwise stated.
-glycerophosphoric acid, 100 µg/ml phenylmethanesulfonyl fluoride,
and 1 µg/ml each of aprotinin and leupeptin, pH 7.35). The lysates
were clarified by centrifugation at 12,000 × g for 10 min at 4 °C. Protein concentrations were determined using the Bio-Rad DC protein assay.
-32P]GTP in 50 mM Tris-HCl, pH
7.4, 2 mM EGTA, 1 mM dithiothreitol, 20% (w/v)
glycerol, 100 mM NaCl, and 500 µM AMP-PNP for
10 min at room temperature. The samples were placed in an ice bath and irradiated with UV light (254 nm) for 15 min, mixed with 5× Laemmli sample buffer, and boiled for 5 min. SDS-PAGE was performed followed by
transfer to nitrocellulose filters and exposure on x-ray film.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-32P]GTP into an ~80-kDa protein,
which we have verified to be TGase based on both protein purification
(18) and immunoprecipitation with an anti-TGase antibody (Fig.
1B, for review see Ref. 21). Consistent with earlier
findings that showed that long term treatments were required for the
up-regulation of TGase activity (1, 7, 8), nearly 24 h of RA
stimulation were needed before increases in TGase expression and
activation were evident (Fig. 1A). We then measured the
ability of RA to activate ERK using an antibody that recognizes only
the phosphorylated forms of ERK1/2. Within 5 min of exposure to the
retinoid, ERK activity could be detected at a level comparable with
that observed with the positive control, EGF. The RA-induced ERK
activation was sustained up to 1 h and then reduced to near basal
activity for the duration of the experiment. From the same cell lysates
used to analyze ERK induction, PI3K activity was also examined using
AKT phosphorylation or activation as a readout. The phosphorylation of
AKT provides a reliable assay for PI3K activation, because it has been
well established that several pro-survival signals up-regulate AKT
phosphorylation in a PI3K-dependent manner (22, 23).
Utilizing an AKT phospho-specific antibody, we found that AKT
phosphorylation was augmented by RA in a time-dependent
fashion. AKT induction coincided with RA-mediated ERK activation,
having maximal activation at 5 min and decreasing gradually to near
background levels by 8 h of stimulation. Others have also
demonstrated that ERK and PI3K activities were enhanced by RA in the
human leukemia cell line HL60 (24, 25) and that inhibiting the activity
of either kinase blocked RA-mediated differentiation. These findings
indicate that retinoid-induced mitogen-activated protein kinase
and PI3K activation are not unique to NIH3T3 cells and suggest that
their signaling capabilities are involved in some aspects of
RA-mediated cellular effects. The differences in the phosphorylation
states of ERK and AKT detected with the phospho-specific antibodies
throughout the duration of the RA time course were likely a result of
posttranslational modifications (i.e. the activation of
kinases and phosphatases) rather than changes in protein expression as
the ERK and AKT protein levels remained constant in each sample. It is
interesting that not only does RA up-regulate similar signaling
pathways as growth factors, the rates of activation of ERK and AKT
induced by RA closely parallel the transient activations of ERK and AKT
following EGF stimulation (26, 27).

View larger version (47K):
[in a new window]
Fig. 1.
RA induces the GTP binding activity of TGase
and the phosphorylation of ERK and PI3K. NIH3T3 cells grown in
complete growth medium for 2 days were placed in low serum medium (1%
calf serum). The following day, the cells were treated with 5 µM RA for various times and then lysed.
A, the activation and expression levels of TGase, ERK,
and PI3K were examined in each of the cell lysates. TGase GTP binding
activity was determined using affinity labeling with radioactive GTP as
described under "Experimental Procedures." Western blot
(WB) analysis using phospho-specific antibodies was used to
measure the activities of ERK and AKT. The blots were stripped and then
reprobed with antibodies that recognized total TGase, ERK, and AKT to
assess the expression levels of each of these proteins.
B, whole cell lysates of cells treated without (
) or
with RA were affinity-labeled with radioactive GTP and then
immunoprecipitated with a TGase antibody (I.P. TGase) or an
ERK antibody (I.P. ERK). SDS-PAGE and transfer to
nitrocellulose membrane were performed on the immunoprecipitations, and
the membrane was exposed to film to monitor the photoincorporation of
[
-32P]GTP by TGase. Expression of the TGase was
detected by probing the membrane with a TGase antibody (WB:
TGase).

View larger version (26K):
[in a new window]
Fig. 2.
LY294002 treatment inhibits
RA-induced TGase expression. NIH3T3 and HL60 cells were grown in
complete growth medium for 2 days, placed in low serum medium
containing 6 µM LY294002 (LY) or 10 µM PD98095 (PD) ± 5 µM RA
for 2 days, and then lysed. The whole cell extracts were used to
determine the expression level of TGase via Western blot
(WB) analysis and TGase GTP binding activity by affinity
labeling assays as outlined under "Experimental Procedures."

View larger version (39K):
[in a new window]
Fig. 3.
Constitutive PI3K activity is not sufficient
to induce chronic TGase expression or activation. Cells were
transiently transfected with vector only, a HA-tagged myristoylated
form of the catalytic subunit of PI3K (HA-p110M), or a
HA-tagged form of the regulatory subunit of PI3K (HA-p85)
and grown in complete growth medium for 1 day. The medium was replaced
with low serum medium ± 5 µM RA, and the cultures
were maintained for another 2 days and then lysed. SDS-PAGE and
transfer to nitrocellulose membrane were performed on the whole cell
extracts. The expression of the PI3K constructs was detected by probing
the blot with a HA antibody, and the expression of TGase was detected
using a TGase antibody. The whole cell extracts were also used in
affinity labeling assays as outlined under "Experimental
Procedures." WB, Western blot.
Because PI3K activation appears to be necessary for RA to up-regulate TGase expression, we next assessed whether continuous PI3K signaling would be sufficient to cause chronic TGase expression and/or activation in mouse fibroblasts. Despite the expression of a constitutively active form of PI3K (a myristoylated form of the p110 catalytic subunit) in fibroblasts, a corresponding increase in TGase expression was not evident (Fig. 3). Furthermore, the RA treatment of cells overexpressing myristoylated p110 up-regulated TGase expression and GTP binding activity to the same extent as control cells, indicating that continuous PI3K activation was not sufficient to sensitize the induction of TGase expression or activation by RA. Similar experiments conducted in NIH3T3 cells stably overexpressing dominant-active forms of the small G-proteins Ras, Rac, or Cdc42 also did not augment the basal level of RA-induced TGase expression or GTP binding (data not shown). We were also interested in determining whether factors that can activate PI3K other than RA might be capable of regulating TGase expression levels. Sustained stimulation of NIH3T3 cells with EGF for 2 days activated PI3K strongly as indicated by AKT phosphorylation (Fig. 1) but failed to produce a detectable increase in TGase protein levels (Fig. 3). These data strongly suggest that although PI3K activity is essential for RA to induce TGase expression, RA must also influence the function of an additional factor(s) in order to increase TGase expression. We expect that at least one of these factors is likely to be under the transcriptional control of a member of the RAR family based on two lines of evidence. First, the activation of this factor seems to be a specific outcome of RA signaling, because both RA and EGF stimulated PI3K activity but only RA was capable of augmenting TGase expression. Several studies have demonstrated that the RARs preferentially bind to and become activated by retinoids (13, 14). Second, it has been well established that the induction of the transcriptional activities of the RARs by binding RA is essential for retinoid-mediated TGase expression (15).
Increases in TGase expression following exposure to RA are invariably
coupled with the induction of the GTP binding activity of the TGase
(Fig. 1) (7, 11). However, the molecular mechanisms that stimulate the
formation of the GTP-bound state of the newly translated TGase protein
are currently unknown. Expanding upon our finding that RA requires
active PI3K to induce TGase expression, we asked whether PI3K might
also affect TGase GTP binding activity independent of the effects on
TGase expression. To examine this possibility, we took advantage of
previous work that showed that expression of exogenous TGase in cells
yielded a TGase species, which was able to bind GTP even without the
addition of the stimulatory factor RA (7). Consistent with this
finding, NIH3T3 cells transiently expressing a TGase construct
incorporated [
-32P]GTP (Fig.
4A, inset) in a manner similar
to the TGase GTP binding activity observed when cells were treated with
RA for several days. When duplicate plates of cells expressing
exogenous TGase were exposed to LY294002 for 2 days, the ability of the
TGase to incorporate [
-32P]GTP was significantly
reduced (Fig. 4A, inset and graph); the average
inhibition in several experiments was ~60%. However, even in the
presence of excess concentrations of LY294002, the GTP binding activity
of the TGase was not completely eliminated (data not shown), suggesting
that a PI3K-independent pathway can contribute to the activation of
TGase GTP binding activity. To ensure that the reduction in the GTP
binding activity of the exogenous TGase by the chemical inhibitor was a
result of down-regulating PI3K activity rather than the result of a
nonspecific inhibitory effect on the TGase molecule, we tested whether
the GTP binding activity of recombinant purified TGase was altered in
the presence of LY294002. Fig. 4B showed that incubating
25-50 ng of recombinant TGase with increasing concentrations of
LY294002 (up to 400 µM) did not change the ability of the
TGase to bind GTP as readout by photoaffinity-labeling with
[
-32P]GTP. How the signaling capability of PI3K
promotes the binding of GTP to the TGase in cells is not understood and
is a current focus of our research. One intriguing possibility is that
PI3K mediates the expression and/or activation of a guanine nucleotide exchange factor for TGase. Once up-regulated, the exchange factor could
promote the binding of GTP to the TGase in a manner analogous to the
function of guanine nucleotide exchange factors on members of the Ras
family of small G-proteins (28). Another possibility may involve the
ability of PI3K signaling to limit the effectiveness of a negative
regulator(s) of TGase activity that is known to exist in cells (7, 21).
The RA-induced stimulation of PI3K activity could produce a signaling
event that would somehow disrupt the interaction of the TGase with the
inhibitory complex, making the TGase accessible for binding GTP.
|
Having established a link between PI3K and TGase activation, we then
examined whether cell fate responses induced by RA would be affected if
PI3K activity was inhibited. Under the stress of serum starvation,
NIH3T3 cells exposed to RA for nearly 2 days displayed a low rate of
apoptosis, whereas the treatment with the related retinoid, HPR,
induced a potent cell death response (Fig.
5). Because RA but not HPR was shown to
enhance TGase expression and activation, it was proposed that this
distinct signaling feature may be important for the anti-apoptotic
effects of RA (7). Consistent with this idea, RA-stimulated cells
pretreated with MDC, a competitive inhibitor of TGase-catalyzed
transanimation, displayed an ~35% decrease in cell viability (Fig.
5), indicating that the exposure of cells to RA could be sensitized to
apoptosis by simply limiting the function of the TGase. Because PI3K
activity is required for the RA-induced up-regulation of TGase activity and TGase activity appears to be critical for the survival effect of
RA, we examined whether the treatment of RA-stimulated cells with
LY294002 gave rise to an increase in cell death. This in fact was the
case as the addition of RA to cells treated with LY294002 resulted in a
significant increase in the number of apoptotic cells. Still, the
extent of apoptosis was always less than that of the accompanying HPR
treatment, most probably because typically some amount of PI3K activity
and corresponding TGase expression and activation persists even in the
presence of the inhibitor. However, TGase expression and activation can
be completely eliminated when combining LY294002 with MDC, thus
yielding a level of apoptosis that was nearly equivalent to that
induced by HPR. Taken together, these data strongly suggest that
PI3K-mediated TGase activation is a key element of the survival
response afforded by RA.
|
TGase activation has largely been associated with programmed cell death
(5, 6, 29); however, more recently, TGase function has been shown
either not to be directly linked to the apoptotic process (8, 30) or to
have an anti-apoptotic role in cells (7). The fact that we have now
demonstrated that RA-mediated TGase expression and activation require
the activation of the well established survival factor PI3K further
implicates TGase in a survival role. At present, we do not know how
PI3K signaling influences the expression of the TGase, although
presumably it will involve the activation of one or more known PI3K
effectors such as ribosomal S6 kinase or AKT. AKT is an especially
interesting possibility, because it has been implicated in promoting
the expression of survival genes by activating the cAMP-responsive
element-binding protein and the nuclear
B transcription factors
(31).
Thus, in summary, we have shown for the first time that RA activates
the signaling molecule, PI3K, and that this activation is essential for
the ability of RA to induce the expression and subsequent activation of
the TGase. How both PI3K and ERK become activated following RA
stimulation is unclear and warrants further investigation. The RARs are
nuclear receptors that upon binding RA become active transcription
factors, which modulate the expression of RA-responsive genes (13, 14).
Although it is generally believed that RA-induced cellular responses
occur via the up-regulation of gene expression, our data imply that RA
is capable of directly activating similar intracellular signaling
cascades as those activated by growth factors. In support of this idea,
RA treatment has previously been reported to increase the activation of
several intracellular signaling proteins including focal adhesion
kinase (32), ERK (24), and PI3K (25). We are beginning to evaluate
whether RA can activate additional signaling cascades that contribute to the up-regulation of TGase expression and/or its activation.
| |
ACKNOWLEDGEMENT |
|---|
We acknowledge the expert secretarial assistance of Cindy Westmiller.
| |
FOOTNOTES |
|---|
* The work was supported in part by National Institutes of Health Postdoctoral Grant F32 GM208052 (to M. A.) and Grant NIH RO1 GM61762 (to R. A. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Molecular
Medicine, VMC, Cornell University, Ithaca, NY 14853-6401. Tel.: 607-253-3888; Fax: 607-253-3659; E-mail: rac1@cornell.edu-email.
Published, JBC Papers in Press, February 19, 2002, DOI 10.1074/jbc.M112259200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
TGase, tissue
transglutaminase;
RA, retinoic acid;
RAR, retinoic acid receptor;
PI3K, phosphoinositide 3-kinase;
ERK, extracellular signal-regulated kinase;
EGF, epidermal growth factor;
HPR, all-trans-N-(4-hydroxyphenyl)retinamide;
MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase;
AMP-PNP, adenosine 5'-(
,
-imino)triphosphate;
HA, hemagglutinin;
MDC, monodansylcadaverine.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Lesort, M.,
Tucholski, J.,
Miller, M. L.,
and Johnson, G. V. W.
(2000)
Prog. Neurobiol.
61,
439-463[CrossRef][Medline]
[Order article via Infotrieve] |
| 2. |
Aeschlimann, D.,
Kaupp, O.,
and Paulsson, M.
(1995)
J. Cell Biol.
129,
881-892 |
| 3. |
Davies, P. J.,
Davies, D. R.,
Levitzki, A.,
Maxfield, F. R.,
Milhaud, P.,
Willingham, M. C.,
and Pastan, I. C.
(1980)
Nature
283,
162-167[CrossRef][Medline]
[Order article via Infotrieve] |
| 4. |
Aeschlimann, D.,
Wetterwald, A.,
Fleisch, H.,
and Paulsson, M.
(1993)
J. Cell Biol.
120,
1461-1470 |
| 5. |
Piacentini, M.,
Fesus, L.,
Farrace, M. G.,
Ghibelli, L.,
Piredda, L.,
and Melino, G.
(1991)
Eur. J. Cell Biol.
54,
246-254[Medline]
[Order article via Infotrieve] |
| 6. |
Oliverio, S.,
Amendola, A.,
DiSano, F.,
Farrace, M. G.,
Fesus, L.,
Nemes, Z.,
Piredda, L.,
Spinedi, A.,
and Piacentini, M.
(1997)
Mol. Cell. Biol.
17,
6040-6048[Abstract] |
| 7. |
Antonyak, M. A.,
Singh, U. S.,
Lee, D. A.,
Boehm, J. E.,
Combs, C.,
Zgola, M. M.,
Page, R. L.,
and Cerione, R. A.
(2001)
J. Biol. Chem.
276,
33582-33587 |
| 8. |
Tucholski, J.,
Lesort, M.,
and Johnson, G. V. W.
(2000)
Neuroscience
102,
481-491 |
| 9. |
Chiocca, E. A.,
Davies, P. J. A.,
and Stein, J. P.
(1988)
J. Biol. Chem.
263,
11584-11589 |
| 10. |
Bertram, J. S.
(1983)
Cancer Surv.
2,
243-262 |
| 11. |
Sporn, M. B.,
and Roberts, A. B.
(1983)
Cancer Res.
43,
3034-3040 |
| 12. |
Piacentini, M.,
Martinet, N.,
Beninati, S.,
and Folk, J. E.
(1988)
J. Biol. Chem.
263,
3790-3794 |
| 13. | Pfahl, M., Apfel, R., Bendik, I., Fanjul, A., Graupner, G., Lee, M.-O., La-, Vista, N., Lu, X.-P., Piedrafita, J., Ortiz, A., Salbert, G., and Zhang, X.-K. (1994) in Vitamins and Hormones (Litwack, G., ed) , pp. 327-392, Academic Press, San Diego, CA |
| 14. | Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994) in The Retinoids: Biology, Chemistry and Medicine (Sporn, M. B. , Roberts, A. B. , and Goodman, O. S., eds), 2nd Ed. , Raven Press, Ltd., New York |
| 15. |
Nagy, L.,
Saydak, M.,
Shipley, N., Lu, S.,
Basilion, J. P.,
Yan, Z.-H,
Syka, P.,
Chandraratna, R. A. S.,
Stein, J. P.,
Heyman, R. A.,
and Davies, P. J. A.
(1996)
J. Biol. Chem.
271,
4355-4365 |
| 16. |
Lu, S.,
Saydak, M.,
Gentile, V.,
Stein, J. P.,
and Davies, P. J. A.
(1995)
J. Biol. Chem.
270,
9748-9756 |
| 17. |
Achyuthan, K. E.,
and Greenberg, C. S.
(1987)
J. Biol. Chem.
262,
1901-1906 |
| 18. |
Singh, U. S.,
Erickson, J. W.,
and Cerione, R. A.
(1995)
Biochemistry
34,
15863-15871[CrossRef][Medline]
[Order article via Infotrieve] |
| 19. |
Lai, T. S.,
Slaughter, T. F.,
Koropchak, C. M.,
Haroon, Z. A.,
and Greenberg, C. S.
(1996)
J. Biol. Chem.
271,
31191-31195 |
| 20. |
Nakaoka, H.,
Perez, D. M.,
Baek, K. J.,
Das, T.,
Husain, A. M.,
Misono, K., Im, M. J.,
and Graham, R. M.
(1994)
Science
264,
1593-1596 |
| 21. |
Singh, U. S.,
and Cerione, R. A.
(1996)
J. Biol. Chem.
271,
27292-27298 |
| 22. |
Bergering, B. T.,
and Coffer, P. J.
(1995)
Nature
376,
599-602[CrossRef][Medline]
[Order article via Infotrieve] |
| 23. |
Franke, F. T.,
Yang, S. I.,
Chan, T. O.,
Datta, K.,
Kazlauskas, A.,
Morrison, D. K.,
Kaplan, D. R.,
and Tsichlis, P. N.
(1995)
Cell
81,
727-736[CrossRef][Medline]
[Order article via Infotrieve] |
| 24. |
Yen, A.,
Roberson, M. S.,
Varvayanis, S.,
and Lee, A. T.
(1998)
Cancer Res.
58,
3163-3172 |
| 25. |
Bertagnolo, V.,
Neri, L. M.,
Marchisio, M.,
Mischiati, C.,
and Capitani, S.
(1999)
Cancer Res.
59,
542-546 |
| 26. |
Antonyak, M. A.,
Moscatello, D. K.,
and Wong, A. J.
(1998)
J. Biol. Chem.
273,
2817-2822 |
| 27. |
Habib, T.,
Hejna, J. A.,
Moses, R. E.,
and Decker, S. J.
(1998)
J. Biol. Chem.
273,
18605-18609 |
| 28. |
Cerione, R. A.,
and Zheng, Y.
(1996)
Curr. Opin. Cell Biol.
8,
216-222[CrossRef][Medline]
[Order article via Infotrieve] |
| 29. |
Oliverio, S.,
Amendola, A.,
Rodolfo, C.,
Spinedi, A.,
and Piacentini, M.
(1999)
J. Biol. Chem.
274,
34123-34128 |
| 30. |
Nanda, N.,
Iismaa, S. E.,
Owens, W. A.,
Husain, A.,
Mackay, F.,
and Graham, R. M.
(2001)
J. Biol. Chem.
276,
20673-20678 |
| 31. |
Brunet, A.,
Datta, S. R.,
and Greenberg, M. E.
(2001)
Curr. Opin. Neurobiol.
11,
297-305[CrossRef][Medline]
[Order article via Infotrieve] |
| 32. |
Zhu, W.-Y.,
Jones, C. S.,
Amin, S.,
Matsukuma, K.,
Haque, M.,
Vuligonda, V.,
Chandraratna, R. A. S.,
and DeLuca, L. M.
(1999)
Cancer Res.
59,
85-90 |
This article has been cited by other articles:
![]() |
S. Masia, S. Alvarez, A. R. de Lera, and D. Barettino Rapid, Nongenomic Actions of Retinoic Acid on Phosphatidylinositol-3-Kinase Signaling Pathway Mediated by the Retinoic Acid Receptor Mol. Endocrinol., October 1, 2007; 21(10): 2391 - 2402. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-A. Jung, H. K. Lee, J. S. Yoon, S.-J. Kim, C. Y. Kim, H. Song, K.-C. Hwang, J. B. Lee, and J. H. Lee Upregulation of TGF-{beta}-Induced Tissue Transglutaminase Expression by PI3K-Akt Pathway Activation in Human Subconjunctival Fibroblasts Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 1952 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamaguchi and H.-G. Wang Tissue Transglutaminase Serves as an Inhibitor of Apoptosis by Cross-Linking Caspase 3 in Thapsigargin-Treated Cells Mol. Cell. Biol., January 15, 2006; 26(2): 569 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yuan, K. Choi, C. Khosla, X. Zheng, R. Higashikubo, M. R. Chicoine, and K. M. Rich Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas Mol. Cancer Ther., September 1, 2005; 4(9): 1293 - 1302. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells Blood, February 15, 2005; 105(4): 1669 - 1677. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lee, Y.-S. Kim, D.-H. Choi, M. S. Bang, T. R. Han, T. H. Joh, and S.-Y. Kim Transglutaminase 2 Induces Nuclear Factor-{kappa}B Activation via a Novel Pathway in BV-2 Microglia J. Biol. Chem., December 17, 2004; 279(51): 53725 - 53735. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Antonyak, A. M. Miller, J. M. Jansen, J. E. Boehm, C. E. Balkman, J. J. Wakshlag, R. L. Page, and R. A. Cerione Augmentation of Tissue Transglutaminase Expression and Activation by Epidermal Growth Factor Inhibit Doxorubicin-induced Apoptosis in Human Breast Cancer Cells J. Biol. Chem., October 1, 2004; 279(40): 41461 - 41467. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Akimov and A. M. Belkin Opposing Roles of Ras/Raf Oncogenes and the MEK1/ERK Signaling Module in Regulation of Expression and Adhesive Function of Surface Transglutaminase J. Biol. Chem., September 12, 2003; 278(37): 35609 - 35619. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kambhampati, Y. Li, A. Verma, A. Sassano, B. Majchrzak, D. K. Deb, S. Parmar, N. Giafis, D. V. Kalvakolanu, A. Rahman, et al. Activation of Protein Kinase C{delta} by All-trans-retinoic Acid J. Biol. Chem., August 29, 2003; 278(35): 32544 - 32551. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Antonyak, C. J. McNeill, J. J. Wakshlag, J. E. Boehm, and R. A. Cerione Activation of the Ras-ERK Pathway Inhibits Retinoic Acid-induced Stimulation of Tissue Transglutaminase Expression in NIH3T3 Cells J. Biol. Chem., April 25, 2003; 278(18): 15859 - 15866. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Boehm, U. Singh, C. Combs, M. A. Antonyak, and R. A. Cerione Tissue Transglutaminase Protects against Apoptosis by Modifying the Tumor Suppressor Protein p110 Rb J. Biol. Chem., May 31, 2002; 277(23): 20127 - 20130. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE O |